AMGN · News · 20260923N

Product / Drug Pipeline Progress

AMGEN INC · 2026-09-23 · Importance 34 · Surprise 42

Amgen’s dazodalibep met the primary endpoint in the Phase 3 OASIZ 301 trial for systemic Sjögren’s disease, demonstrating statistically significant and clinically meaningful improvement in systemic disease activity. Jefferies said the therapy may offer a better safety profile than existing treatments and viewed it as a potential growth opportunity. Amgen did not disclose the treatment difference versus placebo, p-values, or confidence intervals, limiting independent assessment of the benefit magnitude. A second Phase 3 study, OASIZ 303, is expected to conclude in late 2026 in patients with high symptom burden but low systemic activity.

Key facts

• Positive Phase III trial results were reported by Amgen for dazodalibep. source
• Amgen reported positive Phase III trial results for IMDELLTRA. source
• Amgen has a pipeline candidate named MariTide described as promising. source
• Jefferies increased its price target for Amgen to $410 from $367 after dazodalibep showed positive Phase 3 results for systemic Sjögren's disease. source